Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
Published on: November 8, 2024
National Drug Shortages: Remedial Executive and Legislative Initiatives
Eli Y Adashi1, Daniel P O'Mahony2, I Glenn Cohen2
1From the Brown University; Brown University Library; Harvard Law School; and Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University (EYA, DPO, IGC). Eli_Adashi@brown.edu.
Abstract:
Medication shortages constitute an ongoing threat to patient care across the United States and affect nearly every aspect of health care. National drug shortages have been a recurring challenge of the US health care system but were markedly aggravated during the COVID-19 pandemic. Federal executive and legislative efforts to bolster the resiliency of the pharmaceutical supply chain have thus far fallen short. This Commentary reviews the leading executive and legislative initiatives proposed during the 118th Congress and the Biden administration to protect the national drug supply in the hope of avoiding future shortages. It will be up to the new (119th) Congress and presidential administration to take up this issue again and pursue remediation of the nation's drug shortage problem. The health of the nation demands action by policy makers to mitigate drug shortages that give rise to discontinuity of care and thereby to a compromise of the national state of health.
Related Concept Videos
Drug Regulation
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Drug Nomenclature

